ReviewExpert review of respiratory medicine2026
Harnessing breath biomarkers for pneumonia diagnosis and prognosis.
Review in Expert review of respiratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionPneumonia is a major cause of death and disability worldwide. A host of pathogens causes pneumonia, and pneumonia presents with a remarkable heterogeneity of clinical symptoms and signs and has varied outcomes. Current approaches to pneumonia diagnosis and risk stratification lack precision such that there is no universally agreed upon biomarker or scoring system. These limitations have prompted calls for novel, noninvasive, and more precise approaches to better diagnosing pneumonia and predicting outcomes. AREAS COVERED: We performed a comprehensive literature search through PubMed to identify studies reporting on breath biomarkers in pneumonia published up to 31 July 2025. This manuscript explores breath-based metabolomics as a novel approach to biomarker development in pneumonia. It describes breath collection methods, including devices available and types of breath samples for analysis. It reviews the potential role of exhaled breath analysis to expedite pneumonia diagnosis, monitor response to therapy, and predict clinical trajectory. EXPERT OPINION: Breath-based metabolomics could improve the recognition and management of pneumonia. It is a noninvasive, potentially continuous method that provides a direct window into the lung for novel insights into the underlying biology of pneumonia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.